{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:04:50Z","timestamp":1779811490210,"version":"3.53.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CKD-related anemia remains a major complication in patients receiving peritoneal dialysis (PD), with limited treatment options beyond erythropoiesis-stimulating agents. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, has shown promise in correcting CKD-related anemia and modulating iron and metabolic parameters. However, its evidence in PD remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of PubMed, Scopus, and Web of Science from inception to July 20, 2025. We included studies reporting the efficacy and safety of roxadustat in PD. Statistical analysis was performed using Review Manager (RevMan 5.4 for Windows) and R Studio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight studies were included in the meta-analysis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009607). Roxadustat significantly increased hemoglobin at all time points (MD 0.35\u00a0g\/dL, 95% CI 0.28\u20130.41;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), serum iron (MD 0.95 \u00b5mol\/L, 95% CI 0.02\u20131.89;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05), and total iron-binding capacity (MD 6.25 \u00b5mol\/L, 95% CI 3.95\u20138.55;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), and reduced hepcidin (MD \u2212\u200912.28 ng\/mL, 95% CI \u2212\u200921.06 to \u2212\u20093.50;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). No significant effects were observed for ferritin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.49), transferrin saturation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.45), cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07), LDL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14), HDL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.27), triglycerides (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.26), CRP (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.75), systolic blood pressure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.10), or diastolic blood pressure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08). Heterogeneity was low to moderate for most outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Roxadustat is effective in improving hemoglobin and iron metabolism in patients with PD, while exerting neutral effects on lipids, inflammation, and blood pressure. These findings support its role as a promising therapy for CKD-related anemia in PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04723-x","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:44:56Z","timestamp":1779713096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roxadustat for CKD-related anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Omar","family":"Elkoumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elkoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam Khaled","family":"Elbairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Adel T.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"12","key":"4723_CR1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/ckj\/sfad152","volume":"16","author":"J Portoles","year":"2023","unstructured":"Portoles J, Serrano Salazar ML, Gonz\u00e1lez Pe\u00f1a O, Gallego Dom\u00ednguez S, Vera Rivera M, Caro Espada J, et al. Opportunities to improve the management of anemia in peritoneal Dialysis patients: lessons from a National study in routine clinical practice. Clin Kidney J. 2023;16(12):2493\u2013502.","journal-title":"Clin Kidney J"},{"issue":"6","key":"4723_CR2","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/biomedicines12061191","volume":"12","author":"K Badura","year":"2024","unstructured":"Badura K, Janc J, W\u0105sik J, Gnitecki S, Skwira S, M\u0142ynarska E, et al. Anemia of chronic kidney Disease\u2014A narrative review of its Pathophysiology, Diagnosis, and management. Biomedicines. 2024;12(6):1191.","journal-title":"Biomedicines"},{"key":"4723_CR3","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portol\u00e9s","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current Treatments, to future agents. Front Med. 2021;8:642296.","journal-title":"Front Med"},{"key":"4723_CR4","doi-asserted-by":"publisher","first-page":"1274490","DOI":"10.3389\/fphar.2023.1274490","volume":"14","author":"M Roy","year":"2023","unstructured":"Roy M, Saroha S, Sarma U, Sarathy H, Kumar R. Quantitative systems Pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease. Front Pharmacol. 2023;14:1274490.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4723_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000521162","volume":"8","author":"HHL Wu","year":"2022","unstructured":"Wu HHL, Chinnadurai R. Erythropoietin-Stimulating agent hyporesponsiveness in patients living with chronic kidney disease. Kidney Dis. 2022;8(2):103\u201314.","journal-title":"Kidney Dis"},{"issue":"1","key":"4723_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jfma.2013.09.004","volume":"113","author":"SC Hung","year":"2014","unstructured":"Hung SC, Lin YP, Tarng DC. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc. 2014;113(1):3\u201310.","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"4723_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/ki.2011.49","volume":"80","author":"SL Seliger","year":"2011","unstructured":"Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011;80(3):288\u201394.","journal-title":"Kidney Int"},{"issue":"2","key":"4723_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000504850","volume":"6","author":"ZL Li","year":"2020","unstructured":"Li ZL, Tu Y, Liu BC. Treatment of renal anemia with roxadustat: advantages and achievement. Kidney Dis. 2020;6(2):65\u201373.","journal-title":"Kidney Dis"},{"key":"4723_CR9","doi-asserted-by":"crossref","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019 Sept 12;381(11):1001\u201310.","DOI":"10.1056\/NEJMoa1813599"},{"key":"4723_CR10","doi-asserted-by":"crossref","unstructured":"Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L, et al. Hypoxia-inducible factor Prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European renal best practice board of the European renal association. Nephrol Dialysis Transplantation. 2024 Sept;27(10):1710\u201330.","DOI":"10.1093\/ndt\/gfae075"},{"issue":"10","key":"4723_CR11","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.7150\/ijms.97599","volume":"21","author":"N Li","year":"2024","unstructured":"Li N, Cui W, Mu D, Shi X, Gao L, Liu S, et al. Effects of Roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: a retrospective study. Int J Med Sci. 2024;21(10):1806\u201313.","journal-title":"Int J Med Sci"},{"issue":"1","key":"4723_CR12","doi-asserted-by":"publisher","first-page":"2460726","DOI":"10.1080\/0886022X.2025.2460726","volume":"47","author":"T Xu","year":"2025","unstructured":"Xu T, Ruan Y, Liu N, Wang Y, Zang X, Ma Y, et al. Effect of Roxadustat on Lowering blood lipids in peritoneal Dialysis patients with anemia. Ren Fail. 2025;47(1):2460726.","journal-title":"Ren Fail"},{"key":"4723_CR13","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 1st ed. Wiley; 2019 [cited 2025 Sept 22]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/book\/https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"4723_CR14","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009 July;21(jul21 1):b2535\u20132535.","DOI":"10.1136\/bmj.b2535"},{"issue":"oct18 2","key":"4723_CR15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928\u20135928.","journal-title":"BMJ"},{"key":"4723_CR16","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"4723_CR17","doi-asserted-by":"crossref","unstructured":"Bao L, Bian X, Zhang A, Huang J, Ren L, Luo C. Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study. Ann Palliat Med. 2022 June;11(6):2017\u201324.","DOI":"10.21037\/apm-22-555"},{"key":"4723_CR18","doi-asserted-by":"crossref","unstructured":"Cheng S, Zhou T, Yu L, Zhang Z, Chen Y, Zhang M, et al. Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis. Front Med. 2023 June;8:10:1166024.","DOI":"10.3389\/fmed.2023.1166024"},{"key":"4723_CR19","doi-asserted-by":"crossref","unstructured":"Hirai K, Nonaka H, Ueda M, Morino J, Kaneko S, Minato S, et al. Effects of Roxadustat on the anemia and iron metabolism of patients undergoing peritoneal Dialysis. Front Med. 2021 July;7:8:667117.","DOI":"10.3389\/fmed.2021.667117"},{"issue":"3","key":"4723_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3904\/kjim.2023.520","volume":"39","author":"J Liu","year":"2024","unstructured":"Liu J, Li S, Yang F, Li T, Li R, Waheed Y, et al. A retrospective study on the efficacy of Roxadustat in peritoneal Dialysis patients with erythropoietin hyporesponsiveness. Korean J Intern Med. 2024;39(3):488\u2013500.","journal-title":"Korean J Intern Med"},{"issue":"3","key":"4723_CR21","doi-asserted-by":"publisher","first-page":"e0320536","DOI":"10.1371\/journal.pone.0320536","volume":"20","author":"J Liu","year":"2025","unstructured":"Liu J, Zhou K, Meng C, Liu Z, Huang R, Waheed Y, et al. Roxadustat effectiveness versus ESAs in peritoneal Dialysis patients during the COVID-19 pandemic: A retrospective study. PLoS ONE. 2025;20(3):e0320536.","journal-title":"PLoS ONE"},{"issue":"1","key":"4723_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/0886022X.2022.2050754","volume":"44","author":"T Wu","year":"2022","unstructured":"Wu T, Qi Y, Ma S, Zhang L, Pu X, Chen K, et al. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal Dialysis. Ren Fail. 2022;44(1):529\u201340.","journal-title":"Ren Fail"},{"issue":"1","key":"4723_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s40001-023-01465-0","volume":"28","author":"X Zhang","year":"2023","unstructured":"Zhang X, Jia R, Zheng Z, Jiang L, Xu Y, Raj A, et al. Effect of Roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study. Eur J Med Res. 2023;28(1):489.","journal-title":"Eur J Med Res"},{"key":"4723_CR24","doi-asserted-by":"crossref","unstructured":"Zhu XW, Zhang CX, Xu TH, Jiang GN, Yao L. Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia. WJCC. 2021 Sept 16;9(26):7682\u201392.","DOI":"10.12998\/wjcc.v9.i26.7682"},{"issue":"2","key":"4723_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/1744-9987.12888","volume":"24","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of Roxadustat in peritoneal Dialysis chronic kidney disease patients with anemia: A Randomized, phase 3, Multicenter, Open-Label study. Ther Apher Dial. 2020;24(2):115\u201325.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"4723_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","volume":"121","author":"YP Hou","year":"2022","unstructured":"Hou YP, Mao XY, Wang C, Xu ZH, Bu ZH, Xu M, et al. Roxadustat treatment for anemia in peritoneal Dialysis patients: A randomized controlled trial. J Formos Med Assoc. 2022;121(2):529\u201338.","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"4723_CR27","doi-asserted-by":"publisher","first-page":"e15310","DOI":"10.1016\/j.heliyon.2023.e15310","volume":"9","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Zhang P, Yang H, Geng Y, Tang J, Kang Y, et al. Effects of hypoxia-inducible factor Prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis. Heliyon. 2023;9(4):e15310.","journal-title":"Heliyon"},{"issue":"12","key":"4723_CR28","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/toxics12120846","volume":"12","author":"Y Geng","year":"2024","unstructured":"Geng Y, Zhang S, Cao Z, Tang J, Cui H, Dong Z, et al. The efficacy and safety of Roxadustat for anemia in Hemodialysis patients with chronic kidney disease: A Meta-Analysis of randomized controlled trials. Toxics. 2024;12(12):846.","journal-title":"Toxics"},{"issue":"10","key":"4723_CR29","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B, Sch\u00f6mig M, Esposito C, Barratt J, Reusch M, Valluri U, et al. Roxadustat for the maintenance treatment of anemia in patients with End-Stage kidney disease on stable dialysis: A European phase 3, Randomized, Open-Label, Active-Controlled study (PYRENEES). Adv Ther. 2021;38(10):5361\u201380.","journal-title":"Adv Ther"},{"key":"4723_CR30","doi-asserted-by":"crossref","unstructured":"Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021 July;6(7):1829\u201339.","DOI":"10.1016\/j.ekir.2021.04.007"},{"issue":"9","key":"4723_CR31","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","volume":"36","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, et al. Roxadustat for anemia in patients with end-stage renal disease incident to Dialysis. Nephrol Dial Transpl. 2021;36(9):1717\u201330.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4723_CR32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","volume":"33","author":"S Fishbane","year":"2022","unstructured":"Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, et al. Roxadustat versus Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33(4):850\u201366.","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"4723_CR33","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.3390\/jcm13226729","volume":"13","author":"D Fliser","year":"2024","unstructured":"Fliser D, Bhandari S, Ortiz A, Santos V, Khalife N, Jiletcovici A, et al. Roxadustat efficacy and safety in patients receiving peritoneal dialysis: pooled analysis of four phase 3 studies. J Clin Med. 2024;13(22):6729.","journal-title":"J Clin Med"},{"issue":"9","key":"4723_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.34067\/KID.0000000808","volume":"6","author":"FR McCausland","year":"2025","unstructured":"McCausland FR, Waikar SS, Claggett B, McMahon GM, Neto OMV, Rastogi A, et al. Association of different definitions of Erythropoiesis-Stimulating agent hyporesponsiveness with major adverse cardiovascular events. Kidney360. 2025;6(9):1541\u20138.","journal-title":"Kidney360"},{"key":"4723_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.amjcard.2025.07.010","volume":"256","author":"O Elkoumi","year":"2025","unstructured":"Elkoumi O, Elkoumi A, Elbairy MK, Irfan H, Hageen AW, Beddor A, et al. Impact of Statins on mortality and cardiovascular outcomes in Dialysis patients with atherosclerotic cardiovascular disease: A systematic review and Meta-Analysis. Am J Cardiol. 2025;256:49\u201359.","journal-title":"Am J Cardiol"},{"key":"4723_CR36","doi-asserted-by":"crossref","unstructured":"Lo HY, Lin YS, Lin DSH, Lee JK, Chen WJ. Association of statin therapy with major adverse cardiovascular and limb outcomes in patients with end-stage kidney disease and peripheral artery disease receiving maintenance dialysis. JAMA Netw Open. 2022 Sept 1;5(9):e2229706.","DOI":"10.1001\/jamanetworkopen.2022.29706"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04723-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04723-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04723-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:27:25Z","timestamp":1779809245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04723-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4723"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04723-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This article does not contain any studies involving human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Non-applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}